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Abstract 
 
Aim: The aim was to determine whether zein microspheres can act as vaccine 
adjuvants, i.e., increase the immune responses to co-administered immunogens.   
Methodology: Ovalbumin (model antigen)-loaded zein microspheres, blank zein 
microspheres and ovalbumin solution were intramuscularly administered to mice and 
the sera antibody levels were determined by ELISA.  Another group of mice was 
orally dosed with blank zein microspheres, and serum and faecal antibody levels were 
determined. 
Results:  As expected, negligible antibody titres were obtained with the ovalbumin 
solution.  Surprisingly, intramuscular administrations of blank zein microspheres 
elicited high levels of serum IgG which bound to the ovalbumin antigen coated on 
ELISA microtitre plates.  This indicated that anti-zein antibodies had been elicited by 
blank zein microspheres and that these antibodies were cross-reacting with ovalbumin 
antigen coated onto ELISA plates. Such cross-reactivity inhibited the determination of 
the adjuvant activity of zein microspheres, if any. Additional ELISA assays, where 
zein was used as the coating antigen, confirmed the generation of anti-zein antibodies 
by blank zein microspheres, i.e. zein microspheres were immunogenic following 
intramuscular administration. Upon oral administration of blank zein microspheres, 
serum IgG levels remained low but intestinal IgA levels increased following booster 
doses i.e. systemic tolerance, but not mucosal tolerance, to oral zein particles was 
achieved.  
Conclusion:  Zein microspheres are immunogenic when administered intramuscularly 
and orally.   
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Introduction 
 
In the past decades, microspheres - defined as monolithic polymeric matrix systems 
(Couvreur & Puisieux 1993) - have been extensively investigated as 
sustained/controlled release drug and vaccine carriers.  Sustained release of entrapped 
active entity enables a reduced dosing frequency and enhanced patient compliance.  
The use microspheres for vaccine delivery also has the advantages of presenting the 
vaccine in a particulate form, which facilitates vaccine recognition and uptake by 
antigen presenting cells, resulting in enhanced immune responses (Storni et al 2005).  
Consequently, a variety of particulate vaccine delivery systems have been studied 
(Bramwell & Perrie 2005).  Polylactide-co-glycolide (PLGA) has been the polymer of 
choice for the formulation of microspheres as it is already used in biomedical devices 
in man.  However, PLGA particles do suffer from certain disadvantages, such as 
instability of encapsulated proteins (Putney et al 1998; Schwenderman 2002; Jiang et 
al 2005) and a large number of alternative polymers, synthetic and natural, have been 
investigated. 
 
One such polymer is zein, a naturally occurring hydrophobic plant polymer, which is 
biodegradable, has GRAS (Generally Regarded as Safe) status (Anon 1985) and has 
been extensively used in the pharmaceutical, food, agricultural and other industries.  
Zein - the prolamin of maize (Zea mays L.), found in maize germ and endosperm –
consists of a mixture of peptides, which may be divided into several classes. Each 
class differs in solubility, molecular weight, amino acid composition, immunological 
properties, etc. The classification of the different classes of zein protein has led to 
confusion and many nomenclatures have been proposed (Esen 1986, 1987, 1990; 
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Wilson 1985; Landy & Guyon 1984 a,b). In this work, the nomenclature proposed by 
Esen (1986, 1987, 1990) has been employed. According to this nomenclature, zein is 
composed of four classes of protein (α, β, δ and γ). α-zein is the most abundant, 
consists of two polypeptides of estimated MW of 22 and 24 kD, and its amino acid 
composition is similar to that of whole zein (Paulis et al 1969; Paulis & Wall 1977; 
Esen et al 1981). Both β-zein, a methionine-rich polymer of 17 kD, and δ-zein, a 
minor fraction of MW 10 kD, have similar solubility profiles to α-zein. γ-zein is 
composed of two components: one with MW 27 kD and the other with MW 18 kD. It 
is believed, however, that the 18 kD polypeptide is a truncated version of the 27 kD 
peptide.  Microspheres of zein have been formulated as carriers of anti-cancer agents 
(Matsuda et al 1989; Suzuki et al 1989; Mathiowitz et al 1993), the parasiticide, 
ivermectin (Liu et al 2005), the pesticide, abamectin (Demchak & Dybas 1997) and 
essential oils (Parris et al 2005). Films composed of zein microspheres have been 
investigated as a biomaterial in tissue engineering and have shown good 
biocompatibility (Dong et al 2004).  The drug release from the microspheres was 
reported to be low, and indicated the possibility of sustained-release of antigens 
entrapped within zein microspheres.  
 
We therefore investigated zein microspheres as vaccine carriers/adjuvants, using 
ovalbumin as a model antigen.  The need for research into vaccine adjuvants remains 
despite much work in this field, due to the poor immunogenicity of newer and purer 
subunit vaccines, the actual and possible future toxicity of many adjuvants currently 
in research, and the fact that only a handful of adjuvants are currently used in 
commercial vaccines.  The formulation and characterisation of zein microspheres, 
loaded with ovalbumin has been reported (Hurtado-López and Murdan, 2005; 
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Hurtado-López and Murdan in press).  The spherical particles have a smooth and non-
porous surface, a particle diameter of approximately 600nm, and released the loaded 
ovalbumin slowly when incubated in phosphate buffered saline.   
 
The aim of the work reported in this paper was to determine the adjuvanticity of zein 
microspheres. Vaccine carriers should only increase the immune responses to the 
desired antigen, not to non-vaccine proteins, such as the host, food or to itself.  
Therefore, the generation of immune responses to blank zein microspheres, if any, 
following intrasmuscular and oral administrations were also investigated.  
 
 
Materials and Methods 
Animals 
Female BALB/c mice, obtained from B&K Ltd, UK, were maintained on a normal 
mouse diet, which contains maize germ (a source of zein), and were given water ad 
libitum.  All procedures had been approved by the School’s Ethical Review 
Committee and were conducted in accordance with the Home Office standards under 
the Animals (Scientific Procedures) Act, 1986. The experiments were started when 
the mice were eight weeks old and weighed approximately 20 g.   
 
Materials 
Ovalbumin (Grade II), zein, bovine serum albumin (BSA), polyvinyl pyrrolidone MW 
360 000 (PVP 360), phosphate buffered saline (PBS) tablets, Tween 20, potassium 
chloride, anti-mouse IgA (a-chain specific) peroxidase conjugate, anti-mouse IgG 
(whole molecule) peroxidase conjugate, hydrogen peroxide (30% v/v aqueous 
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solution), 2,2’-azino-bis (3-ethylbenzothiazoline-6-sulphonic acid) diammonium salt 
(ABTS) tablets, heparin and sodium dodecyl sulphate (SDS) were obtained from 
Sigma, UK. Di-sodium hydrogen orthophosphate, citric acid, potassium hydrogen 
orthophosphate and sodium chloride were purchased from BDH Laboratory Supplies, 
UK. Other chemicals were of reagent grade and were used as received. ELISA 96-
well microtitre plates were purchased from Dynatech, UK.  Double distilled water 
was used throughout.  
 
Preparation of blank and ovalbumin-loaded zein microspheres 
Zein microspheres were prepared by a coacervation method based on the solubility 
properties of zein, as previously described (Hurtado-Lopez & Murdan, 2005).  
Briefly, to prepare blank (i.e. without ovalbumin) zein microspheres, zein (62.5 mg) 
was dispersed in 10 ml of 100% ethanol with gentle stirring. This produced a coarse 
dispersion. 5 ml each of Tween 20 (2.5 %v/v) and of polyvinyl pyrrolidone (PVP 40, 
4 %w/v) aqueous solutions were then added to the ethanolic dispersion. Consequently, 
a fine aqueous-alcoholic zein suspension was formed. Ethanol was removed by rotary 
evaporation at 90 mBar and 40 ºC for 10-15min and a fine aqueous suspension of zein 
microspheres was produced. The latter were stored as a suspension until needed.  The 
average diameter of the blank microspheres was found to be 1356 ± 36.4 nm, with a 
polydispersity of 0.662 ± 0.218 (Hurtado-Lopez & Murdan, 2005). 
 
Ovalbumin-loaded zein microspheres were produced as above, except for the addition 
of ovalbumin (50 mg) with zein (62.5mg) into 10 ml of 100% ethanol (which gave 
rise to a coarse dispersion upon stirring), and the addition of a small amount (0.3 ml) 
of 1% w/v aqueous sodium hydroxide solution.  The latter was added as it was found 
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to prevent the aggregation of ovalbumin and zein that otherwise occurred upon the 
addition of the two proteins into 100% ethanol. Following the addition of Tween 20 
and PVP solutions and the removal of ethanol, ovalbumin-loaded zein microspheres 
were produced. The average particle diameter was 607.47 ± 48.3 nm, with a 
polydispersity of 0.386 ± 0.166.   The experimental loading of ovalbumin in the 
microspheres was 23.90 %; the loaded ovalbumin is expected to be entrapped within 
the microsphere matrix.  The unloaded ovalbumin was present either as non-uniform 
aggregates or dissolved in the aqueous medium.  The unloaded ovalbumin was not 
removed from the microsphere suspension prior to administration to experimental 
animals; thus the latter received some free and some entrapped ovalbumin. 
 
Intramuscular immunization 
To determine the adjuvanticity of zein microspheres, mice (in groups of 5) were 
intramuscularly dosed with:  
i) ovalbumin-loaded zein microsphere suspension (150 µg ovalbumin in 30 µl 
suspension),  
ii) ovalbumin dissolved in saline (150 µg ovalbumin in 30µl solution), or 
iii) blank zein microsphere suspension (30 µl).   
The microsphere suspensions were vortexed immediately before injection and a single 
injection in the quadriceps was used to administer the dose.   Booster intramuscular 
administrations were given twelve weeks after the primary immunisation, in an 
identical way.  To determine immune responses, the animals were bled from the tail 
vein, 7 weeks after the first dose and again, 1, 4 and 7 weeks after the booster dose.  
The blood samples were allowed to clot overnight in a refrigerator, after which, they 
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were centrifuged at 21 000 rpm for 10 min in a table-top centrifuge. Sera were 
collected and stored at –70 ºC until assayed. 
 
Oral immunisation  
To determine whether oral administration of zein microspheres gives rise to immune 
responses against zein, mice were orally dosed with 100 µl of blank zein microsphere 
suspension, containing 625 µg of zein protein, on three consecutive days following 
overnight fasting. Identical booster doses were administered on days 29, 30 and 31 of 
the study.  The animals were bled 4 weeks after priming and again, 4 weeks after 
boosting, and serum samples were obtained as described above. At the same time 
intervals, fresh faecal samples were collected from individual mice placed in 
metabolic cages. The faeces were added to PBS pH 7.4, the mixtures were 
homogenized, centrifuged at 21 000 rpm for 15 min in a table-top centrifuge, and the 
supernatants were collected and stored at –70 ºC until assayed.  A control group of 
non-immunised animals was used to obtain control faecal and blood samples.  
 
Determination of antibody levels by ELISA 
Serum and faecal samples were analysed for anti-ovalbumin and anti-zein IgG and 
IgA antibodies respectively by a standardised ELISA method. Microtitre ELISA 
plates were coated with 100 µl per well of antigen solution.  The latter was either 
ovalbumin 1 %w/v in PBS pH 7.4 or zein 1% w/v in 60% v/v ethanol. Zein, a water-
insoluble protein, was dissolved in 60% ethanol as the adsorption of zein to 
polystyrene microtitre plates when dissolved in aqueous alcohols has been 
demonstrated, as has the subsequent quantitative measurement of the protein 
following a regular ELISA assay (Conroy & Esen 1984; Chirdo et al 1995). 
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Following overnight incubation at 4 ºC, the plates were washed three times using 
phosphate buffered saline-Tween 20 (0.05% Tween 20), then once again with double 
distilled water.  The plates were then blocked at 37 ºC for 1 h, with 100 µl per well of 
aqueous blocking solution:  PVP 360 1% w/v (when ovalbumin was the antigen) or 
bovine serum albumin 1 % w/v (when zein was the antigen). Plates were washed as 
described. Serum or faecal samples (100 µl /well, diluted 16x) were placed in the top 
row of ELISA plates, serial double dilutions were conducted in the other rows and the 
plates were incubated for 1 h at 37 ºC. Following washing, 100 µl per well of anti-
mouse IgA or IgG peroxidase conjugate (diluted 1:1 000 in PBS pH 7.4) was added to 
the ELISA plates, which were incubated at 37 ºC for 1 h. Plates were washed, freshly 
prepared ABTS/hydrogen peroxide solution was added (50 µl per well) and the plates 
were incubated at 37 ºC for 30 min.  The reaction was stopped by the addition of 1% 
w/v sodium dodecyl sulphate aqueous solution (50 µl/well) and the plates were read at 
405 nm in an ELISA reader (Opsys MR, Dynex Technologies).  To compare the 
levels of antibodies generated by the different formulations, the optical density 
readings obtained for the serum that was diluted 16x were used. 
 
 
Statistical analyses 
One-Way ANOVA, followed by post-hoc Tukey HSD tests were used to compare the 
anti-ovalbumin IgG titres generated by intramuscularly administered ovalbumin 
solution, and ovalbumin-loaded and blank zein microspheres.  Kruskal-Wallis, 
followed by Nemenyi tests were conducted to compare the primary and secondary 
anti-zein IgG titres generated by intramuscularly administered ovalbumin-loaded and 
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blank zein microspheres.  Mann Whitney U tests were conducted to compare the 
primary and secondary immune responses to orally administered blank zein 
microspheres. Results were considered statistically significant when P < 0.05. 
 
Results and Discussion 
The zein microspheres (blank and ovalbumin-loaded) were prepared by a simple 
coacervation method. Spherical zein particles with a smooth surface were produced, 
as observed by scanning electron microscopy (Figure 1).    The average diameter of 
the blank microspheres was found to be 1356 ± 36.4 nm, with a polydispersity of 
0.662 ± 0.218, while that of ovalbumin-loaded particles was 607.47 ± 48.3 nm, with a 
polydispersity of 0.386 ± 0.166. The experimental loading of ovalbumin in the 
microspheres was 23.90 % (Hurtado-Lopez & Murdan, 2005).  
 
Immune responses to intramuscularly administered  formulations 
To determine whether zein microspheres enhance the immunogenicity of ovalbumin, 
and thereby act as an adjuvant, the serum anti-ovalbumin IgG levels generated 
following administration of ‘free’ and ‘microsphere-loaded’ ovalbumin were 
measured. Blank zein microspheres were used as controls. The primary and secondary 
(at weeks 1, 4 and 7 after the booster dose) IgG titres of the 3 preparations are shown 
in Table 1.  To determine statistical differences, if any, between the titres of the 3 
preparations, One-Way ANOVA was conducted for each time-point. From the table, 
it can be seen that: 
 
i) as expected, administration of free, non-encapsulated ovalbumin gave rise to very 
low levels of primary and secondary antibodies, ovalbumin being poorly 
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immunogenic in the free form.  Booster doses of the free antigen significantly 
increased the levels of anti-ovalbumin IgG; these levels however decreased with time. 
At all time points, the antibody titres generated by the solution were significantly 
lower than those of the microsphere formulations. 
 
ii) administration of both blank and ovalbumin-loaded zein microspheres elicited a 
higher IgG response, especially following the booster administrations.  Serum IgG 
levels remained high for several weeks following the booster administration.  
Interestingly, there was an IgG response to blank zein microspheres.  The primary IgG 
levels were higher (P < 0.05) than those elicited by the ovalbumin-loaded zein 
microspheres, while the secondary IgG levels (at all time points) were not 
significantly different to those elicited by ovalbumin-loaded zein microspheres (P > 
0.05). 
 
The high antibody responses generated by blank zein microspheres indicate that anti-
zein antibodies had been generated and that these antibodies were binding (non-
specifically) to ovalbumin antigen coated onto the ELISA microtitre plate wells.  The 
non-specific binding of anti-zein antibodies to ovalbumin antigen coated on ELISA 
microtitre plate walls meant that any possible increase in anti-ovalbumin IgG titres, 
due to microencapsulation of the antigen into zein particles could not be detected.  
Thus, from this study, the adjuvant activity of zein particles, if any, cannot be 
ascertained. 
 
Generation of antibodies by blank zein microspheres was surprising, given that the 
experimental mice were fed a standard mouse diet which includes zein.  It is well 
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known that feeding of dietary proteins predominantly induces tolerance i.e. feeding 
does not result in immune responses to the proteins; in addition when the same protein 
is subsequently administered via an immunogenic route, such as the intramuscular 
one, injurious local or systemic immune responses are not elicited (Mowat & Weiner, 
1999).  To investigate into the immune responses generated to zein particles further, 
additional ELISA assays, where the microtitre plate wells were coated with zein 
antigen, were conducted to measure the primary and secondary anti-zein IgG levels 
elicited by blank and ovalbumin-loaded zein microspheres.  The serum IgG levels are 
shown in Table 2.  To determine significant differences, if any, between the primary 
and the secondary titres of the two formulations, Kruskal-Wallis, followed by 
Nemenyi’s tests were conducted.   It was found that the anti-zein IgG titres generated 
by blank and by ovalbumin-loaded zein microspheres were not significantly different 
from each other, for both primary and secondary response (P > 0.05).  In addition, for 
both formulations, the anti-zein IgG titres increased significantly following the 
booster dose (P < 0.05).   
 
The results confirm that feeding of dietary zein did not induce tolerance to zein 
particles when the latter were administered intra-muscularly.  This could be due to the 
fact that zein was administered in the particulate form, the latter is known to be more 
immunogenic than the soluble state.  The generation of antibodies by zein particles 
show that zein, when administered intramuscularly in a particulate form, is 
immunogenic and raises concerns over the use of these particles as drug and vaccine 
delivery systems.  Drug carriers should be non-immunogenic to avoid concerns about 
their biocompatibility (Hillery, 2001).  For the same reason, vaccine delivery systems 
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(some of which, such as microspheres, also act as adjuvants) should also be non-
immunogenic.   
 
Immune responses to orally administered zein microspheres 
Oral tolerance (partial or complete immunological non-responsiveness to orally 
administered antigen) to zein particles would allow their use as oral drug/vaccine 
delivery vehicles.  In order to determine the possibility of oral tolerance to zein 
microspheres, a group of 5 mice was orally dosed with blank zein microspheres and 
the immune responses (serum IgG and intestinal mucosal IgA to zein antigen) were 
monitored.  Significant differences between the primary and secondary responses, if 
any, were determined using Mann Whitney U tests.  
 
The primary and secondary serum IgG titres were low and similar to those in naïve 
mice. The serum IgG titres can therefore be assigned to the presence of zein in the 
mouse feed, rather than to the zein microspheres.  Anti-zein IgG titres did not increase 
following the booster dose (P > 0.05) i.e. orally administered zein particles did not 
induce a systemic immune response and instead, systemic tolerance to oral zein 
particles was induced. 
 
In contrast, the intestinal mucosal IgA response did not show the induction of 
tolerance. The primary IgA levels were low and similar to the levels in naïve mice.  
However, following the booster dose, IgA levels increased significantly (P < 0.05; 
titre doubled from 0.32 ± 0.001 to 0.62 ± 0.05).   The generation of IgA antibodies to 
zein particles is expected to limit the application of the latter as oral drug/vaccine 
carriers, as the secretory IgA molecules will bind to zein particles, and thereby 
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prevent the latter’s adherence to the mucosal surface and subsequent uptake by 
Peyer’s Patches. 
 
Our results - the absence of a strong serum IgG response concomitantly with the  
presence of a significant IgA response - reflect reports by other researchers 
(Challacombe & Tomasi 1980;  McGhee et al 1999) of systemic unresponsiveness, 
concomitant with mucosal responsiveness to oral antigens. IgA responses seem to be 
more resistant to the induction of oral tolerance (McGhee et al 1999). 
 
 
Conclusions 
The aim of the study reported in this paper was to investigate the potential of zein 
microspheres as vaccine delivery systems.  Ovalbumin was used as a model antigen.  
The adjuvanticity of zein microspheres could not be ascertained in this study.  
However, their immunogenicity was demonstrated.  Following the intramuscular 
administration of blank and ovalbumin-loaded zein microspheres, a significant IgG 
response to zein was elicited. Following oral administration of blank zein 
microspheres, a significant anti-zein IgG response was not observed, but the intestinal 
anti-zein IgA titres was found to double, i.e. oral administration induced systemic, but 
not mucosal, tolerance to zein particles. Thus, this study, which shows the 
immunogenicity of zein particles, raises questions about their potential application as 
drug and vaccine delivery vehicles. 
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Figure legends 
Figure 1: Scanning electron micrograph of ovalbumin-loaded zein microspheres. 
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Table 1:  The primary and secondary anti-ovalbumin IgG titres generated following the 
intramuscular administration of ovalbumin solution, ovalbumin-loaded zein microspheres 
and blank zein microspheres in mice.  Mean ± S.D are shown, n=5. 
 
 
 
Anti-ovalbumin IgG titre 
Secondary response (week(s) after booster dose) 
 
Formulation Primary 
response 
1 week 4 weeks 7 weeks 
Ovalbumin 
solution 
0.11 ± 0.01 0.89 ± 0.09 0.38 ± 0.04 0.34 ± 0.13 
Ovalbumin-
loaded zein 
microspheres 
0.15 ± 0.03 1.74 ± 0.32 1.36 ± 0.37 1.36 ± 0.25 
Blank zein 
microspheres 
0.21 ± 0.03 1.59 ± 0.21 1.64 ± 0.34 1.11 ± 0.09 
 
Figures
 2 
 
Table 2:  The primary and secondary anti-zein IgG titres generated following the 
intramuscular administration of blank and of ovalbumin-loaded zein microspheres in 
mice.  Mean ± S.D are shown, n=5. 
 
 
Anti-zein antibody titre  
Formulation Primary 
response 
Secondary 
response  
Ovalbumin-
loaded zein 
microspheres 
0.25 ± 0.03 0.91 ± 0.08 
Blank zein 
microspheres 
0.24 ± 0.03 0.82 ± 0.13 
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Dear Dr Murdan, 
 
Thank you for submitting your paper to the Journal of Pharmacy and Pharmacology.  As 
you will see from the enclosed report, the referees have raised concerns regarding several 
aspects of the manuscript.  On this basis, I invite you to submit a revised version of the 
paper that takes into account the points raised by the referees, whereupon a decision will 
then be made regarding acceptability. 
 
I would therefore be grateful if you would provide the following, within two weeks of 
receipt of this notice:  
A revised version of the manuscript, taking into account the referees and editorial 
comments, and a list of changes outlining your response to the above comments. 
 
For your guidance, reviewers' comments are appended below. 
 
To submit a revision, go to http://jpp.edmgr.com/ and log in as an Author.  You will see a 
menu item called Submission Needing Revision.  You will find your submission record 
there.  
 
Yours sincerely 
 
Grainne McCarron 
Editorial Office 
Journal of Pharmacy and Pharmacology 
 
Reviewers' comments: 
 
Dear Sudax, 
 
I am writing to inform you that your manuscript has been provisionally accepted for 
publication in the special issue of the JPP following major revision.  In particular, the 
referees have raised a number of scientific points that require clarification.  The authors 
should individually address these points in the response to the editors.  Furthermore, the 
revised sections of the manuscript should be clearly highlighted (underlined) in the 
revised manuscript.  This is to facilitate the editorial decision.  The manuscript will be 
returned to the original referees for comments and a decision made whether the 
manuscript is suitable for publication.   
 
In addition to the points raised by the referees, please address the following editorial 
concerns 
 
(i) Details of ethical committee approval for the study should be included  
Details are now given in materials section. 
 
* Response to referee comments
 2 
(ii)    Please ensure that each point raised by the referees and the editor is individually 
addressed and highlighted in the revised manuscript and these changes are detailed in a 
separate letter to the editor 
Done 
 
(iii)   Please pay particular attention to the comments raised regarding statistical analysis  
(as raised by the statistical editor).  As the recommended statistical methods are different 
from the ones that you have employed in the manuscript, this may result in alterations in 
the results and discussions sections.   
Yes, the stats have been done and alterations in manuscript have been underlined. 
 
(iv)  To optimise space in the journal, I would be grateful if the number of figures is 
reduced by combining some of these into a single table.  For example figures 3-5 would 
be better presented in tabular form.  Alternatively, figures 4 and 5 could be deleted and 
the values included into the written section of the results. 
Figures 1-3 have been changed to 2 tables (1 for anti-ovalbumin IgG, the other for anti-
zein IgG). Figures 4 and 5 have been deleted and data is presented in the text. 
 
(v)  Please reduce the length of the manuscript where apropriate. 
Done 
 
(vi)  Please include a separate conclusions section 
This is now done. 
 
At this stage may I thank you for your ongoing support of the JPP.    
 
David 
Professor David S. Jones  
Editor  
The Journal of Pharmacy and Pharmacology 
 
STATISTICAL EDITOR'S REPORT 
 
In this current paper statistical methods have been defined, although some of these 
methods are not appropriate to the experimental design. These details are described 
below: 
 
General Comments Concerning Your Experimental Design 
(i)     In the section entitled Statistical Analysis you have described the use of a series of 
two sample tests for the quantification of the outcomes of this study.  Unfortunately as 
some of the figures/tables contain more than two treatments, this approach is incorrect as 
it will indirectly increase the likelihood of producing a type 1 error, i.e. rejecting the null 
hypothesis whenever it is indeed correct.  Therefore, to negate this problem, a multiple 
hypothesis test should be used.  If the sample size is greater than 5, the data are normally 
distributed and the variances of the different treatments are equal then the parametric 
Analysis of Variance (ANOVA) should be performed.  If these assumptions cannot be 
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fulfilled then a non-parametric multiple comparisons test, e.g. the Kruskal-Wallis test, 
should be employed. 
 
Suggested examples of these instances are provided below. 
 
(ii)    In Figure 1 the effect of the various formulations on the titre should be analysed 
using a Kruskal-Wallis test.  Individual differences between the formulations may be then 
evaluated using a suitable post hoc test, e.g. Nemenyi's test or Dunn's test.  As stated 
above it is incorrect it is incorrect to perform a series of two sample tests. 
 
(iii)   In figure 2 the effect of the various formulations and time on the titre should be 
analysed using Friedman's test.  Individual differences between the formulations and time 
may be then evaluated using a suitable post hoc test, e.g. Nemenyi's test or Dunn's test.  
As stated above it is incorrect it is incorrect to perform a series of two sample tests. 
 
Alternatively, the effect of formulation on tirte at each time point may be statistically 
analysed using the Kruskal-Wallis test.  Individual differences between the formulations 
may then be determined using Dunn's test. 
 
This suggestion was taken up.  The effect of the different formulations on titre at each 
time point was analysed. One-way ANOVA, followed by post hoc Tukey tests was used 
(instead of Kruskal-Wallis and Dunn’s test) as the number of replicates was 5, the data 
were normally distributed and the variances of the different treatments were equal. 
 
(iv)  The effsct of formulation and immunisation number should be analysed using a 
Kruskal-Wallis test.  Individual differences between the formulations may be then 
evaluated using a suitable post hoc test, e.g. Nemenyi's test or Dunn's test.  As stated 
above it is incorrect it is incorrect to perform a series of two sample tests. 
 
Kruskal-Wallis test, followed by Nemenyi’s have been conducted to analyse differences 
between the primary and secondary anti-zein titres of blank and ovalbumin-loaded zein 
microspheres. 
 
(v)  The data presented in Figures 4 and 5 may be statistically analysed using the Mann 
Whitney U test. 
This is now done. 
 
If you require further assistance may I recommend that you consult the following text: 
 
Pharmaceutical Statistics by Jones, DS, The Pharmaceutical Press (2002). 
 
Alternatively, as part of this service, you may contact the JPP office (jpp@qub.ac.uk) 
with any questions. 
 
 
 4 
Reviewer #1: In present,aluminium adjuvant is used as most vaccine carriers. It is 
necessary that find a new and effective adjuvant in place of traditional aluminium 
adjuvant.The paper must be corrected as follows before it is accepted. 
 
(1) Authors should add data on the immunity effect compared aluminium adjuvant with 
zein microspheres in the paper.  
It is true that aluminium is used at present.  However, it is known that alum has 
limitations, such as, failure to enhance the immune response in certain vaccines e.g. 
influenza and alum is thought not to be the best adjuvant for small-size peptide vaccines 
(Lindblad, in The Theory and Practical Application of Adjuvants, ed; D E S Stewart-Tull, 
Wiley, Chichester, 1995, pp21-35).  Thus, alum is not a ‘gold standard’ that all new 
adjuvants must compare with.  The reviewer is right in pointing out that a traditional 
adjuvant could have provided comparisons; this would somewhat enable the comparisons 
of the myriad of adjuvants currently in research.  Some researchers in the field use 
Freund’s Adjuvant as a positive control.  There is no consensus on a ‘gold standard’ and 
we did not conduct experiments using aluminium, therefore, cannot compare the 
immunity of zein microspheres with that of alum.   
 
(2)Authors should add laser particle distribution figure and scanning electron 
microscopy(SEM) of zein microspheres in order that readers can understand the content 
of the paper. 
OK, SEM is now provided.   
Laser particle distribution is not added as an average particle size is given: 3 different 
microsphere samples were sized; each sample was sized 3 times.   
A new (short) paragraph (page 11, para 2) has been added in the results and discussion 
section to help readers understand the content of the paper. 
 
(3)Authors should add error trendline on fig.1,2,3 and 4. 
The figures have been changed to tables. Standard deviations are shown in all cases. 
 
 
Reviewer #2: Referee Report 
Comments for authors 
 
Contribution to the field 
Moderate - will make a limited contribution to the field  
 
Soundness of methodology 
More information required regarding statistical analysis  
This is now provided 
 
More information required regarding regulatory approval for experimental work 
This is now given in the Materials section. 
 
Soundness of interpretation 
Issues associated with interpretation 
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Has been addressed 
 
Quality of written manuscript 
Figures and Tables require revision 
These have been revised. 
 
Please include a detailed written commentary below: 
 
This is a preliminary work on the immunogenicity of zein microspheres, but should be 
publish (after massive review), since describe the vainness of zein based system for 
drug/vaccine delivery. The observations of course undermine the value of the authors two 
publications as well, which are "in press". 
 
The following points should be addressed: 
 
1       Define zein! 
Zein is a prolamin of maize.  This was included in the original manuscript.  Some more 
information regarding zein’s nature has now been included in the revised manuscript, but 
it is quite difficult to define zein. 
 
2       Abstract: Results - rewrite and explain! 
Has been rewritten and explained. 
 
 
3       P7: purpose of NaOH? 
Sodium hydroxide was added as it was found to prevent the aggregation of ovalbumin 
and zein that otherwise occurred upon the addition of the two proteins into 100% ethanol. 
In the presence of sodium hydroxide, ovalbumin and zein remained dispersed in the 
liquid medium until the removal of ethanol, at which point zein precipitated into 
microspheres.  The purpose of NaOH has now been added in the text. 
 
4       Justification of the doses (very big) 
Ovalbumin is often used as a model antigen due to its availability and its low cost, 
certainly compared to antigens such as hepatitis B surface antigen.  The large dose of 
ovalbumin is fairly common as it is poorly immunogenic, again compared to antigens 
such as hepatitis surface antigen and influenza subunits. 
 
 
5       P 10: paragraph 2; P 11: paragraph 3, 4, 5: explain! 
 
Page 10, para 2 – because mice feed includes zein, the experimental animals had a low 
and constant levels of anti-zein antibody in the sera.  The inherently present anti-zein 
antibodies led to background readings that were higher than empty cells and therefore 
each animal’s pre-immunisation serum was assayed every time.  I agree that the 
paragraph is not very clear.  I’ve gone back to the raw data and decided to use the 
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absorbance readings for the revised version (instead of the serum dilution that gives a 
reading below an arbitrary value). 
 
Page 11,para 3-5 
 
Now on page 12 , sections are re-written. 
 
6       P 12; last paragraph: similar levels of "anti-ovalbumin"! 
The sections have been re-written, after revised calculations 
 
7       P 13: first paragraph; p 14 second paragraph: explain! 
 
P13, first para – revised calculations and interpretations have led to a revised paragraph – 
see page 12,  para 3. 
 
P 14, para 2:  
I have re-written to explain: In the revised manuscript, see page 12, last para, 13, para 1-
2, page 14, para 2 and page 15 para 1-2. 
 
 
8       Error bars! 
OK, Standard deviations are now shown. 
 
9       What are the numbers  in the figs (especially Figs 4 and 5) 
Numbers are now shown in tables and in the text 
 
10      There are unnecessary repetitions from the authors' "in press" papers 
OK, sorry. Repetitions have been removed. 
 
11      Meaningless speculations (P 12-15) 
The speculations have been removed. 
 
12      P 17: paragraph 2: what type of immune response? 
The type of immune response has been clarified. 
 
 
Importantly the manuscript should be massively cut back and published as a "Short 
communication". 
Manuscript has been massively cut back. I have not changed the format to that of a ‘Short 
communication’ as it is perhaps too long for a short communication and this has not been 
suggested by the Editor. 
